Prevalence and Risk Factors of Poor Immune Recovery Among Adult HIV Patients Attending Care and Treatment Centre in Northwestern Tanzania Following the Use of Highly Active Antiretroviral Therapy: a Retrospective Study

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2017 Jun 10

PMID 28595630

Citations 19

Authors

Daniel W Gunda

Semvua B Kilonzo

Erasmus Kamugisha

Engelbert Z Rauya

Bonaventura C Mpondo

Affiliations

Soon will be listed here.

Abstract

Background: Highly Active Antiretroviral therapy (HAART) reverses the effect of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) by durably suppressing viral replication. This allows CD4 gain to levels that are adequate enough to restore the body's capability to fight against opportunistic infections (OIs). Patients with poor immune recovery have been shown to have higher risk of developing both AIDS and non AIDS related clinical events. This study aimed at assessing the proportions and risk factors of poor immune recovery in adult HIV-infected patients on 48 months of HAART attending care and treatment center (CTC) in northwestern Tanzania.

Methods: A retrospective analysis of adult HIV patients' data attending CTC at Sekou Toure hospital and who initiated HAART between February 2004 and January 2008 was done. Poor immune recovery was defined as a CD4 count less than 350 cells/µl on follow up as used in other studies.

Results: A total of 734 patients were included in the study. In this study 50.25% of patients attending CTC at Sekou Toure hospital were found to have poor immune recovery. The risk of developing inadequate immune recovery was independently associated with male gender, age older than 50 years, low baseline CD4 counts, and advanced World Health Organization (WHO) clinical stage.

Conclusions: Poor immune recovery is prevalent among adult HIV patients attending CTC at Sekou Toure hospital in Northwestern part of Tanzania and opportunistic infections are common in this sub group of patients. Clinicians in resource limited countries need to identify these patients timely and plan them for targeted viral assessment and close clinical follow up to improve their long term clinical outcome.

Citing Articles

Incomplete Immune Reconstitution and Traditional Chinese Medicine in Patients with HIV/AIDS: Challenges and Perspectives.

Ding X, Fan L, Xu L, Ma X, Meng P, Li J Infect Drug Resist. 2024; 17:5827-5838.

PMID: 39737090 PMC: 11683152. DOI: 10.2147/IDR.S497083.

Evaluation of Treatment Outcomes Among Individuals on Highly Active Antiretroviral Therapy in KwaZulu-Natal, South Africa.

Muzumbukilwa T, Manimani R, Mushebenge A, Vagiri R, Nlooto M AIDS Res Treat. 2024; 2024:8834740.

PMID: 39691492 PMC: 11651757. DOI: 10.1155/arat/8834740.

Fertility desire and associated factors among antiretroviral therapy users in South Gondar Zone, Northwest Ethiopia, 2022.

Mitiku A, Yirdaw B, Alem H, Yazie Ferede W, Erega B SAGE Open Med. 2024; 12:20503121241283347.

PMID: 39529896 PMC: 11552051. DOI: 10.1177/20503121241283347.

Investigating the Determinants of Mortality before CD4 Count Recovery in a Cohort of Patients Initiated on Antiretroviral Therapy in South Africa Using a Fine and Gray Competing Risks Model.

Mashiri C, Batidzirai J, Chifurira R, Chinhamu K Trop Med Infect Dis. 2024; 9(7).

PMID: 39058196 PMC: 11281671. DOI: 10.3390/tropicalmed9070154.

Evaluation of the effects of Artemisia Annua L. and Moringa Oleifera Lam. on CD4 count and viral load among PLWH on ART at Mbarara Regional Referral Hospital: a double-blind randomized controlled clinical trial.

Twinomujuni S, Atukunda E, Mukonzo J, Nicholas M, Roelofsen F, Ogwang P AIDS Res Ther. 2024; 21(1):22.

PMID: 38627722 PMC: 11020329. DOI: 10.1186/s12981-024-00609-4.

References

Mocroft A, Vella S, Benfield T, Chiesi A, Miller V, Gargalianos P . Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998; 352(9142):1725-30. DOI: 10.1016/s0140-6736(98)03201-2. View

Kaufmann G, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P . Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005; 41(3):361-72. DOI: 10.1086/431484. View

Hunt P, Deeks S, Rodriguez B, Valdez H, Shade S, Abrams D . Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003; 17(13):1907-15. DOI: 10.1097/00002030-200309050-00009. View

Luz P, Grinsztejn B, Velasque L, Pacheco A, Veloso V, Moore R . Long-term CD4+ cell count in response to combination antiretroviral therapy. PLoS One. 2014; 9(4):e93039. PMC: 3973681. DOI: 10.1371/journal.pone.0093039. View

Gaardbo J, Hartling H, Gerstoft J, Nielsen S . Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol. 2012; 2012:670957. PMC: 3312328. DOI: 10.1155/2012/670957. View

Lau B, Gange S, Moore R . Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr. 2006; 44(2):179-87. DOI: 10.1097/01.qai.0000247229.68246.c5. View

Raboud J, Montaner J, Conway B, Rae S, Reiss P, Vella S . Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998; 12(13):1619-24. DOI: 10.1097/00002030-199813000-00008. View

Baker J, Peng G, Rapkin J, Abrams D, Silverberg M, MacArthur R . CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008; 22(7):841-8. PMC: 3618460. DOI: 10.1097/QAD.0b013e3282f7cb76. View

Autran B, Carcelain G, Li T, Blanc C, Mathez D, Tubiana R . Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997; 277(5322):112-6. DOI: 10.1126/science.277.5322.112. View

10.

Althoff K, Justice A, Gange S, Deeks S, Saag M, Silverberg M . Virologic and immunologic response to HAART, by age and regimen class. AIDS. 2010; 24(16):2469-79. PMC: 3136814. DOI: 10.1097/QAD.0b013e32833e6d14. View

11.

Garcia F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M . Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004; 36(2):702-13. DOI: 10.1097/00126334-200406010-00007. View

12.

Brooks J, Kaplan J, Holmes K, Benson C, Pau A, Masur H . HIV-associated opportunistic infections--going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009; 48(5):609-11. DOI: 10.1086/596756. View

13.

Cuzin L, Delpierre C, Gerard S, Massip P, Marchou B . Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years. Clin Infect Dis. 2007; 45(5):654-7. DOI: 10.1086/520652. View

14.

Le Moing V, Thiebaut R, Chene G, Sobel A, Massip P, Collin F . Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med. 2007; 8(3):156-63. DOI: 10.1111/j.1468-1293.2007.00446.x. View

15.

Nanzigu S, Kiguba R, Kabanda J, Mukonzo J, Waako P, Kityo C . Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans. HIV AIDS (Auckl). 2013; 5:309-19. PMC: 3857165. DOI: 10.2147/HIV.S50614. View

16.

Egger M, May M, Chene G, Phillips A, Ledergerber B, Dabis F . Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360(9327):119-29. DOI: 10.1016/s0140-6736(02)09411-4. View

17.

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

18.

Mzileni M, Longo-Mbenza B, Chephe T . Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital. Pol Arch Med Wewn. 2008; 118(10):548-54. View

19.

Yeni P, Hammer S, Hirsch M, Saag M, Schechter M, Carpenter C . Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004; 292(2):251-65. DOI: 10.1001/jama.292.2.251. View

20.

Alexaki A, Liu Y, Wigdahl B . Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res. 2008; 6(5):388-400. PMC: 2683678. DOI: 10.2174/157016208785861195. View